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ABSTRACT
Mortality and morbidity are still high in cardiovascular disease (CVD). Myocardial ischemia reperfusion injury 
leading to myocardial infarction is one of the most frequent causes of the death in humans. Atherosclerosis 
and generation of reactive oxygen species through oxidative stress is the major risk factor for CVD. From the 
literature collection, it has been identiﬁ  ed that moderate consumption of red wine helps in preventing CVD 
through several mechanisms, including increasing the high-density lipoprotein cholesterol plasma levels, 
decreasing platelet aggregation, by antioxidant effects, and by restoration of endothelial function. The aim of 
this review is to discuss the accumulating evidence that suggests that red wine possesses a diverse range of 
biological actions and may be beneﬁ  cial in the prevention of CVD.
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INTRODUCTION
Since ancient times, cardiovascular disease (CVD) has 
become a known, life-threatening problem for the world. 
The risk factors and higher mortality from CVD have been 
proved without doubt from the well-developed countries 
of Western Europe, North America and East Asia, as 
well as for the vast majority of developing countries and 
even the large urban centers of sub-Saharan Africa.[1] The 
highest majority of risk factors for this overall mortality 
are industrial exposure according to their profession, 
changing dietary habits, lifestyle and increasing obesity. 
Moreover, tobacco smoking is highly prevalent and risk 
factors for atherosclerosis tend to occur earlier in life, 
accounting for earlier presentation of CVD events.[1] 
CVD is a leading cause of mortality and is responsible 
for one-third of the global deaths. Nearly 85% of the 
global mortality and disease burden from CVD is borne by 
low- and middle-income countries. In India, for example, 
approximately 53% of the CVD deaths are in people 
younger than 70 years of age; in China, the corresponding 
ﬁ  gure is 35%. The majority of the estimated 32 million 
heart attacks and strokes that occur every year are caused 
by one or more of the following cardiovascular risk 
factors – hypertension, diabetes, smoking, high levels of 
blood lipids and physical inactivity – and most of these 
CVD events are preventable if meaningful action is taken 
against these risk factors.[2] The prevalence of coronary 
artery disease (CAD) in urban North India varies from 
7% to 10%[3,4] compared with 3% in USA.[5] The CAD 
rates in South India are two-folds higher than that in 
North India, with Kerela reporting 14% in urban and 7% 
in rural Thiruvananthapuram.[6,7]
A recent report from the World Health Organization 
(WHO) stated that mortality from CVD in countries of 
Sothern Asia, including India, Pakistan and Bangladesh, 
is not as high as that of Central Asian countries, but is 
signiﬁ  cantly higher than that of East Asian countries.[8] 
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Large variation, however, likely exists within these countries 
between the urban and nonurban populations.
Epidemiological studies have shown that consumption 
of foods and beverages rich in natural polyphenols, 
including those presented in grape fruit, vegetables, tea 
or red wine, is associated with lower incidence of CVDs 
and, especially, with ischemic heart disease.[9,10] Moderate 
wine consumption markedly decreased the cardiovascular 
and cerebrovascular ischemic events, which has been 
proven by many epidemiological studies. Red wine may 
exert its effect by different mechanisms, such as the ability 
to raise the high-density lipoprotein (HDL) levels, to 
increase the antioxidant plasmatic potential, to improve 
endothelium-dependent vasodilation and to inhibit platelet 
aggregation and leukocyte adhesion [Figure 1]. Particularly, 
nonalcoholized red wine has a protective mechanism 
due to its active components like polyphenols, quercetin 
and resveratrol. The protective mechanism of these 
components was already proven by many human and 
animal studies.[11] The present review is aimed at compiling 
data based on the reported works on red wine and the 
promising active principles of red wine to prevent CVDs.
RED WINE: A POTENT ANTIOXIDANT
For many years, the emphasis has been on the relationship 
between serum total cholesterol levels and the risk of 
CVD. However, the focus has recently shifted to oxidative 
stress induced by reactive oxygen species (ROS) and 
nitrogen-reactive species as important key players in the 
etiology and pathogenesis of various chronic diseases, 
including CVD.[12] Antioxidant nutrients are believed to 
slow down the progression of atherosclerosis due to their 
ability to inhibit the damaging oxidative processes.[13,14] 
Epidemiological and prospective studies have shown that 
consumption of antioxidant vitamins such as vitamin E 
and ß-carotene could reduce the risk of CVD.[15] Clinical 
trials also suggest a reduced risk of CVD with vitamin E 
supplementation.[16] The protective effect of vitamin E 
can be ascribed to its antioxidant properties. Observations 
that men and women with CVD show lower levels of 
circulating antioxidants have led scientists to support the 
proposed protective role of antioxidants in the prevention 
and management of CVD.[13] Red wine-active principles 
like red wine polyphenols, resveratrol and quercetin have 
experimental cardioprotective properties[17] and may 
counter one of the mechanisms underlying its antioxidant 
potential. The cardioprotective properties of individual red 
wine components are discussed below.
Red wine polyphenols
Many research and epidemiological studies have shown 
that intake of polyphenols as grape juice and red wine 
is associated with a reduced risk of CVD. The most 
active polyphenol present in red wine is ﬂ  avonoids, and 
it is important due to its putative antioxidant properties. 
The cardiovascular beneﬁ  ts of red wine ﬂ  avonoids are 
explained in the French Paradox phenomenon as well as 
in the Mediterranean diet.[10]
Several studies have documented a protective role of 
moderate wine consumption (15.5–31 g alcohol/day) 
in both vascular and nonvascular diseases. Different 
mechanisms may be responsible for these beneficial 
effects, including increases in the HDL-cholesterol plasma 
levels, decreased platelet aggregation, antioxidant effects 
and restoration of endothelial function by ﬂ  avonoids. 
Numerous cross-sectional, observational and controlled 
studies reveal a range of red wine effects on the different 
aspects related to CVD. In a recent research, it has 
been reported that red wine elicits different metabolic, 
autonomic and endothelial responses among individuals 
with hypercholesterolemia or arterial hypertension and 
healthy controls.[18]
Chronic administration of moderate amounts of red 
wine has been associated with a protective effect on 
the cardiovascular system.[19] Impaired endothelium-
dependent relaxation in both animals and humans is 
playing a major role in the development of CVD, such as 
atherosclerosis and hypertension.[20] Generation of ROS is 
one of the factors for endothelium dysfunction, particularly 
superoxide anions, which reduce the bioavailability of nitric 
oxide (NO).[21-24] Although red wine polyphenols have 
antihypertensive properties, the possibility that they prevent 
the oxidative stress-induced endothelial dysfunction 
remains to be determined. In one research, it has been  Figure 1: Cardioprotective action of red wine173 Journal of Cardiovascular Disease Research Vol. 1 / No 4
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reported that intake of red wine polyphenols prevents 
Angiotensin (Ang) II-induced hypertension and endothelial 
dysfunction. Prevention of vascular nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase induction and 
preservation of arterial NO availability during Ang II 
administration likely contribute to this effect.[19] Red wine 
polyphenols and a grape skin extract also reduced the blood 
pressure in NG -nitro-L-arginine methyl ester (L-NAME) 
and desoxycorticosterone acetate (DOCA) salt-induced 
hypertensive rats.[25,26]
In another study, it has been reported that chronic 
administration of resveratrol (a red wine polyphenol) 
enhances the endothelium-dependent relaxation in 
spontaneously hypertensive rats, and the protective action 
might be due to an increase in the bioavailability of NO.[27] In 
recent research, by using female spontaneous hypertensive 
rats, it was reported that chronic administration of red wine 
polyphenols brings about a reduction in blood pressure 
and vascular dysfunction through reduction in vascular 
oxidative stress.[28]
Inﬂ  ammation plays a vital role in the pathogenesis of 
atherosclerosis, which is a known risk factor for CVD. 
High levels of ﬁ  brinogen and C-reactive protein (CRP), 
both markers of inﬂ  ammation, are associated with a risk of 
developing CVD. In one randomized controlled crossover 
trial, it has been reported that red wine consumption 
markedly decreases the level of ﬁ  brinogen, but it does not 
have any effect on the CRP level.[29]
The effects of short-term oral administration of red wine 
polyphenolic compounds (20 mg/kg/day for 7 days) on the 
hemodynamics, ex vivo cardiac responsiveness and ischemia 
reperfusion injury were investigated in rats. From this study, 
it has been concluded that short-term treatment with red 
wine polyphenols decreases blood pressure and cardiac 
responsiveness and protects against postischemic infarction 
via decreased oxidative stress. All the above effects of red 
wine polyphenols are sensitive to NO synthase inhibition, 
which implies an involvement of the NO-dependent 
pathway. This study suggests a basis for the beneﬁ  cial 
effects of red wine against CVD.[9] The same research 
group already reported that the in vivo cardiovascular 
action of red wine and also the oral administration of red 
wine polyphenols was able to produce a decrease in blood 
pressure in normotensive rats.[9,29] This hemodynamic effect 
was associated with an enhanced endothelium-dependent 
relaxation and induction of the expression of inducible 
NO synthase and cyclooxygenase 2 within the arterial 
wall. Moreover, red wine polyphenols accelerated the 
regression of blood pressure and improved the structural 
and functional cardiovascular changes, including cardiac 
ﬁ  brosis, in hypertensive rats.[25,30]
In another study, it has been reported that red wine 
polyphenolic compounds exert a powerful protective 
effect on the endothelial cells from the injury caused by 
carbon tetrachloride (CCl4). This effect was documented 
by decreased endothelemia, with corresponded to the 
diminished endothelial cell swelling and detachment 
evaluated by histology of the vascular intima.[31] The 
endothelium-protective effect may be one of the key 
factors that contribute to the preventive action of red 
wine on CVDs. Hozumi et al.[32] reported that daily intake 
of red wine polyphenols may beneﬁ  t patients with or 
without CVD by increasing the coronary microcirculation. 
In patients with CAD, 250 ml of de-alcoholized Greek 
red wine decreased the arterial stiffness and improved 
the augmentation index, as derived from arterial wave 
reﬂection patterns. A similar dose of de-alcoholized red 
wine decreased the adverse postsmoking arterial wave 
reﬂections and lessened the rise in systolic blood pressure. 
Brachial artery ﬂow-mediated vasodilation was improved 
by 250–500 ml of de-alcoholized red wine.[33]
Several epidemiological studies suggest that moderate 
alcohol intake, especially red wine, decreases cardiac 
mortality due to atherosclerosis. The alcohol effect is 
described by a J curve, suggesting that moderate drinkers 
may beneﬁ  t while abstainers and heavy drinkers are at 
higher risk.[34] Wine drinkers have higher HDL levels than 
that of nonwine drinkers. The ingestion of red wine is 
associated with an increase in the antioxidant activity in the 
serum, an increase in apolipoprotein A-1 and a decrease 
in the atherogenic agent lipoprotein (a), mainly due to the 
presence of ﬂ  avonoids and stilbenes. It has been further 
suggested that this increase in the antioxidant activity in 
patients regularly drinking red wine may be the primary 
factor inhibiting LDL oxidation, which, in turn, reduces 
atherosclerotic complications.
RESVERATROL
Interest in this compound has expanded in recent years, 
when numerous epidemiological studies showed an 
inverse correlation between red wine consumption and 
incidence of CVDs. Accumulating evidence indicates 
that resveratrol may confer a protective action on the 
cardiovascular system. The cardiovascular beneﬁ  ts of 
resveratrol may relate to protecting the heart cells from 
ischemia reperfusion injury, inhibiting platelet aggregation 
and decreasing plasma triglycerides and cholesterol 174 Journal of Cardiovascular Disease Research Vol. 1 / No 4
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accumulation in the aorta. Furthermore, it can also relax 
the coronary arteries. It seems likely that resveratrol 
might be partly responsible for the cardiovascular beneﬁ  ts 
associated with wine consumption.[30,35] Resveratrol is a 
potent vasodilator and, in several researches, it has been 
reported that the vasorelaxant properties of resveratrol 
might be due to NO-mediated relaxation.[36] Novakovic 
et al.[37] reported that resveratrol induces relaxation of 
the human internal mammary artery (HIMA) rings 
without endothelium. It seems likely that 4-AP- and 
margatoxin-sensitive K+ channels located in the vascular 
smooth muscle mediated the relaxation of HIMA 
produced by resveratrol. In addition, the vasodilator 
effect of resveratrol through NO-mediated endothelium-
dependent relaxation in spontaneous hypertensive rats 
was also reported.[27] A separate experiment showed 
that chronic resveratrol administration enhanced the 
endothelium-dependent vasodilation in ovariectomized, 
stroke-prone, spontaneously hypertensive rats.[38]
Resveratrol shortened the duration of action potential in 
papillary muscles in normal guinea pig and also decreased 
the maximal velocity of phase 0 depolarization in partially 
depolarized papillary muscles. In addition, resveratrol 
inhibited delayed-after depolarization and triggered 
activity induced by ouabain and high Ca2+ in the papillary 
muscle of guinea pigs in a dose-dependent manner.  [39-44] 
In another research, it was found that resveratrol inhibited 
the spontaneous discharges of neurons in the CA1 area 
of rat hippocampal slices. These effects were likely due 
to a decrease of calcium inﬂ  ux.[45] Zheng et al.[46] reported 
that resveratrol decreased the intracellular calcium 
concentration in rat cardiac myocytes. The inhibition of 
voltage-dependent Ca2+ channel and tyrosine kinase and 
alleviation of Ca2+ release from the sarcoplasmic reticulum 
(SR) are possibly involved in the effects of resveratrol on 
rat ventricular myocytes. Intake of resveratrol as red wine 
also increases the production of platelet-dependent NO 
and, in this way, it decreases the proinﬂ  ammatory pathway 
of p38MAPK thus inhibiting ROS production and, 
ultimately, platelet function. This activity may contribute to 
the beneﬁcial effects of moderate wine intake on ischemic 
CVD.[11]
Resveratrol may exert a protective effect against cell death 
through many signaling pathways. Hwang et al.[47] reported 
that resveratrol may exert a protective effect on damage to 
heart muscle through modulation of the AMP-activated 
kinase (AMPK) signaling pathway. Resveratrol induced a 
strong activation of AMPK and inhibited the occurrence 
of cell death caused by treatment with H2O2. Under the 
same conditions, inhibition of AMPK using dominant 
negative AMPK constructs dramatically abolished the 
effect of resveratrol on cell survival in H2O2-treated cardiac 
muscle cells. These results indicate that resveratrol-induced 
cell survival is mediated by AMPK in H9c2 cells, and may 
exert a novel therapeutic effect on oxidative stress induced 
in cardiac disorders.
Ray et al.[48] reported that resveratrol can ameliorate 
myocardial ischemia reperfusion injury. In this research, 
they found that administration of resveratrol to the rat 
provides cardioprotection by decreasing the oxidative stress 
generated in the ischemic-reperfused myocardium. The 
antiischemic effect of resveratrol in another study states 
that the resveratrol-treated hearts showed better functional 
recovery at reperfusion and signiﬁ  cant vasodilation, but 
no variation in high-energy phosphates. This suggests 
that long-term moderate resveratrol consumption could 
play an important role in late cardioprotective effects.  [49] 
A preliminary study carried out by the same research 
group reported that 10 min of resveratrol infusion (10 
μM) in Langendorff-perfused rat hearts caused a 40% 
decrease in the baseline phosphorylation potential without 
affecting contractility. The level of efﬂ  uent adenosine 
was increased by 68%, and paralleled a 50% increase in 
coronary ﬂ  ow. They suggested that an increase in the 
adenosine bioavailability is involved in resveratrol-mediated 
cardioprotection.[49]
The dose-dependent activity of resveratrol was evaluated 
by Das et al.[50] by using the ischemic myocardium in rats. 
The results thus indicate that at, lower doses, resveratrol 
exerts survival function by upregulating the antiapoptotic 
and redox proteins Akt and Bcl-2, while at higher doses, it 
potentiates a death function by downregulating the redox 
proteins and upregulating the proapoptotic proteins.
In another study, it has been reported that resveratrol 
prevents leukocyte recruitment and endothelial barrier 
disruption induced by a number of superoxide-dependent 
proinﬂammatory stimuli, including ischemia and 
reperfusion, hypoxanthine and xanthine oxidase (HX/XO) 
or platelet activating factor. These salutary effects appear 
to be related to the antioxidant properties of resveratrol 
and contribute to the cardioprotective actions associated 
with the consumption of red wine.[51]
The protective role of resveratrol in ischemia reperfusion 
injury is well deﬁ  ned by many researchers. The mitochondrial 
permeability transition pore (mPTP) opening has been 
proposed to play an important role in myocardial ischemia/
reperfusion injury. The mPTP remains closed during 
ischemia but opens at the onset of reperfusion, and 175 Journal of Cardiovascular Disease Research Vol. 1 / No 4
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modulation of the mPTP opening at early reperfusion 
can protect the heart from reperfusion injury. Because 
resveratrol protects the heart through a NO-dependent 
mechanism, and NO has been demonstrated to prevent 
the mPTP opening, it is possible that resveratrol could 
modulate the mPTP opening at reperfusion.[52]
QUERCETIN
Quercetin is one of the most important ﬂ  avonoids present 
in red wine. The antioxidant and protective mechanisms 
in various ischemic conditions were proved by many 
researches. It has been reported that quercetin inhibited 
thrombocyte aggregation[53] and had an antihypertensive 
effect through vasodilator action on the vascular smooth 
muscles.[54] The studies that focused on the antioxidant 
efﬁ  ciency of ﬂ  avonoids against ischemia/reperfusion 
(I/R) injury have demonstrated that quercetin possesses 
robust protective effects in renal, cerebral and hepatic 
I/R models.[55-57] Quercetin was also demonstrated to 
improve the contractile function of the left ventricle in 
experimental myocardial infarction with subsequent 24-h 
reperfusion.[58] Ikizer et al. reported that quercetin has the 
capacity to protect the myocardial tissue against global 
ischemia and reperfusion injury. In instances where the 
molecule is administered for the purpose of acute therapy, 
this cardioprotective effect of a signiﬁ  cant degree can be 
observed, and the protective action might be due to its 
antioxidant and cytoprotective actions.
CONCLUSION
CVDs are now a current major problem in causing mortality 
in both Western and developing countries. Oxidative 
stress associated with atherosclerosis and endothelium-
dependent vascular inﬂ  ammation plays a major role in the 
development of CVD. Red wine contains antioxidative 
components like resveratrol, proanthocyanidine, quarcetin, 
etc. and these active components exert protective functions 
like free radical scavenging effects, decreasing the oxidative 
stress and reducing the inﬂ  ammatory atherosclerotic lesion 
in both animals and humans, which is evident in this review. 
From these ﬁ  ndings, it has been concluded that red wine 
as a diet supplement might be beneﬁ  cial for cardiovascular 
risk factors.
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